Goal 3: Advance Translational Research

To facilitate innovation and accelerate research translation, knowledge dissemination, and implementation science that enhances public health.

Goal 3: Advance Translational Research

The need for funding priorities and emphasis on valve disease and large-animal preclinical studies

Investigators need NHLBI support for programs that transform our approach to heart valve disease to mechanism-based prevention with large-animal preclinical studies through: an NHLBI-sponsored sponsored Heart Valve Network; development of models of genetic and acquired valve disease; a study section devoted to valve disease; and RFAs and RFPs based on Task Force priorities in mitral valve disease.

Submitted by (@rlevine)

Voting

2 net votes
4 up votes
2 down votes
Active

Goal 3: Advance Translational Research

Neglect of Valuable Heart Health Data

Routine bypass surgery generates left ventricle pressure and volumetric flow data which can be modeled by estimated parameters capable of determining a heart health index. This capability is also available online for the surgeon's

guidance and is applicable to any heart chamber.

Submitted by (@woneill)

Voting

-6 net votes
4 up votes
10 down votes
Active

Goal 3: Advance Translational Research

Leveraging PEPFAR infrastructure for CVDs

How do we go about leveraging existing infrastructure, such as PEPFAR, to reduce the risk of HLBS diseases among HIV patients and other vulnerable populations? • Common goals and deliverables between NHLBI and partners will need to be identified • The best return on investment of NHLBI funds will need to be determined • Feasible T4 translation interventions in PEPFAR funded studies utilizing HIV populations with HLBS ...more »

Submitted by (@nhlbiforumadministrator)

Voting

-1 net votes
7 up votes
8 down votes
Active

Goal 3: Advance Translational Research

Develop biomarker panel to predict CVD risk in -omics era

There is a need to utilize the vast data generated in -omics research to develop biomarker panels for better prediction of cardiovascular disease (CVD) risks. •Cardiovascular diseases develop over decades and different panels of markers may be required for different stages •Lead molecules as potential biomarkers need to be selected by a panel of experts •Standard procedures about sample preparation, data acquisition, ...more »

Submitted by (@nhlbiforumadministrator)

Voting

7 net votes
14 up votes
7 down votes
Active